Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001171843-22-002563
Filing Date
2022-04-13
Accepted
2022-04-13 07:23:48
Documents
6
Period of Report
2021-12-31

Document Format Files

Seq Description Document Type Size
1 FORM 6-K f6k_041322.htm 6-K 7774
2 EXHIBIT 99.1 exh_991.htm EX-99.1 553848
3 EXHIBIT 99.2 exh_992.htm EX-99.2 10811
4 EXHIBIT 99.3 exh_993.htm EX-99.3 10683
5 GRAPHIC xortx.jpg GRAPHIC 10195
6 GRAPHIC exh991_p5.jpg GRAPHIC 12834
  Complete submission text file 0001171843-22-002563.txt   616087
Mailing Address SUITE 2400 - 745 THURLOW STREET VANCOUVER A1 V6E 0C5
Business Address SUITE 2400 - 745 THURLOW STREET VANCOUVER A1 V6E 0C5 403-607-2621
XORTX Therapeutics Inc. (Filer) CIK: 0001729214 (see all company filings)

IRS No.: 000000000 | State of Incorp.: A1 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-40858 | Film No.: 22823654
SIC: 2834 Pharmaceutical Preparations